On March 29, 2021, INmune Bio Inc. (the "Company"), reported that it entered into financial advisory agreement with National Securities Corporation ("National") (Filing, 8-K, INmune Bio, MAR 29, 2021, View Source [SID1234577268]). Pursuant to the Agreement, National will provide, on a non-exclusive basis, such financial and other advisory services, as the Company may reasonably request and National deems necessary or appropriate in connection with the Agreement . National shall in the course of the engagement: organize ‘non-deal’ roadshows each comprising presentations to retail offices and institutional investors; provide access to National Securities’ Biotechnology Research Analyst for discussions about the strategy and positioning of the Company; provide access to National Securities’ professional staff for discussions relating to investor relations strategies; and assist in the preparation and dissemination of information regarding the Company and its activities and prospects, including, but not limited, to investor kits and presentations to retail and institutional investors, with the goal of promoting increased name recognition for the Company and familiarity with the Company’s business model, activities and strategies. The Agreement is for a period of 12 months and National shall be paid a fee of $91,666 per month.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!